Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOG.
HADJI, P.; Aapro, Matti S.; BODY, J.J.et al.
2017 • In Journal of Bone Oncology, 23 (7), p. 1-12
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer. Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOG..pdf
Breast cancer; Osteoporosis; Endocrine treatment; Fracture
Abstract :
[en] Background: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated
bone loss (AIBL).
Patients and methods: A systematic literature review identified recent advances in the management of AIBL.
Results with individual agents were assessed based on trial design, size, follow-up, and safety.
Results: Several fracture related risk factors in patients with EBC were identified. Although, the FRAX algorithm includes fracture risk factors (RF) in addition to BMD, it does not seem to adequately address the effects of AIBL. Several antiresorptive agents can prevent and treat AIBL. However, concerns regarding compliance and longterm safety remain. Overall, the evidence for fracture prevention is strongest for denosumab 60 mg s.c. every 6 months. Additionally, recent studies as well as an individual patient data meta-analysis of all available
randomized trial data support additional anticancer benefits from adjuvant bisphosphonate treatment in postmenopausal women with a 34% relative risk reduction in bone metastasis and 17% relative risk decrease in breast cancer mortality that needs to be taken into account when advising on management of AIBL.
Conclusions: In all patients initiating AI treatment, fracture risk should be assessed and recommendation with regard to exercise and calcium/vitamin D supplementation given. Bone-directed therapy should be given to all patients with a T-score<−2.0 or with a T-score of<–1.5 SD with one additional RF, or with ≥2 risk factors (without BMD) for the duration of AI treatment. Patients with T-score>−1.5 SD and no risk factors should be managed based on BMD loss during the first year and the local guidelines for postmenopausal osteoporosis.
Compliance should be regularly assessed as well as BMD on treatment after 12 - 24 months. Furthermore, because of the decreased incidence of bone recurrence and breast cancer specific mortality, adjuvant bisphosphonates are recommended for all postmenopausal women at significant risk of disease recurrence.
Disciplines :
General & internal medicine
Author, co-author :
HADJI, P.
Aapro, Matti S.
BODY, J.J.
GNANT, M.
BRANDI, M.L.
Reginster, Jean-Yves ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOG.
[1] Ginsburg, O., Bray, F., Coleman, M.P., et al. The global burden of women's cancers: a grand challenge in global health. Lancet, 2016.
[2] Guise, T.A., Bone loss and fracture risk associated with cancer therapy. Oncologist 11 (2006), 1121–1131.
[3] Kim, H.J., Yoon, T.I., Chae, H.D., et al. Concurrent gonadotropin-releasing hormone agonist administration with chemotherapy improves neoadjuvant chemotherapy responses in young premenopausal breast cancer patients. J. Breast Cancer 18 (2015), 365–370.
[4] Nicks, K.M., Fowler, T.W., Akel, N.S., et al. Bone turnover across the menopause transition: the role of gonadal inhibins. Ann. N.Y. Acad. Sci. 1192 (2010), 153–160.
[5] Hadji, P., Body, J.J., Aapro, M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol. 19 (2008), 1407–1416.
[6] Goldhirsch, A., Ingle, J.N., Gelber, R.D., et al. Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20 (2009), 1319–1329.
[7] Winer, E.P., Hudis, C., Burstein, H.J., et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23 (2005), 619–629.
[8] Bjarnason, N.H., Hitz, M., Jorgensen, N.R., Vestergaard, P., Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol. 47 (2008), 747–754.
[9] Vestergaard, P., Rejnmark, L., Mosekilde, L., Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif. Tissue Int. 82 (2008), 334–340.
[10] Early Breast Cancer Trialists' Collaborative, G., Dowsett, M., Forbes, J.F., et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386 (2015), 1341–1352.
[11] Coleman, R., Body, J.J., Aapro, M., et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann. Oncol. 25:Suppl 3 (2014), iii124–iii137.
[12] Hadji, P., Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit. Rev. Oncol. Hematol. 69 (2009), 73–82.
[13] Hadji, P., Cancer treatment-induced bone loss in women with breast cancer. Bonekey Rep., 4, 2015, 692.
[14] Hadji, P., Asmar, L., van Nes, J.G., et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane adjuvant multinational (team) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J. Cancer Res. Clin. Oncol. 137 (2011), 1015–1025.
[15] Lee, S.J., Kim, K.M., Brown, J.K., et al. Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer. Calcif. Tissue Int. 97 (2015), 551–559.
[16] Colzani, E., Clements, M., Johansson, A.L., et al. Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br. J. Cancer 115 (2016), 1400–1407.
[17] Kim, W., Chung, Y., Kim, S.H., et al. Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol. Metab. (Seoul) 30 (2015), 58–64.
[18] Hadji, P., Ziller, M., Kieback, D.G., et al. Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann. Oncol. 20 (2009), 1203–1209.
[19] Kyvernitakis, I., Rachner, T.D., Urbschat, A., et al. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J. Cancer Res. Clin. Oncol. 140 (2014), 1671–1680.
[20] Kyvernitakis, I., Knoll, D., Struck, M., et al. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. J. Cancer Res. Clin. Oncol. 140 (2014), 159–166.
[21] Howell, A., Adjuvant aromatase inhibitors for breast cancer. Lancet 366 (2005), 431–433.
[22] Coleman, R.E., Banks, L.M., Girgis, S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup exemestane Study (IES): a randomised controlled Study. Lancet Oncol. 8 (2007), 119–127.
[23] Goss, P.E., Ingle, J.N., Martino, S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97 (2005), 1262–1271.
[24] Coates, A.S., Keshaviah, A., Thurlimann, B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25 (2007), 486–492.
[25] Coleman, R.E., Banks, L.M., Girgis, S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup exemestane Study (IES): a randomised controlled Study. Lancet Oncol. 8 (2007), 119–127.
[26] Forbes, J.F., Cuzick, J., Buzdar, A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9 (2008), 45–53.
[27] Rabaglio, M., Sun, Z., Price, K.N., et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann. Oncol. 20 (2009), 1489–1498.
[28] Amir, E., Seruga, B., Niraula, S., et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J. Natl. Cancer Inst. 103 (2011), 1299–1309.
[29] Bliuc, D., Nguyen, N.D., Milch, V.E., et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301 (2009), 513–521.
[30] Edwards, B.J., Gradishar, W.J., Smith, M.E., et al. Elevated incidence of fractures in women with invasive breast cancer. Osteoporos. Int. 27 (2016), 499–507.
[31] Gnant, M., Denosumab and fracture risk in women with breast cancer – author's reply. Lancet 386 (2015), 2057–2058 (all A-i.).
[32] Edwards, B.J., Raisch, D.W., Shankaran, V., et al. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin. Cancer Res. 17 (2011), 560–568.
[33] Melton, L.J. 3rd, Hartmann, L.C., Achenbach, S.J., et al. Fracture risk in women with breast cancer: a population-based study. J. Bone Min. Res. 27 (2012), 1196–1205.
[34] Bouvard, B., Legrand, E., The dilemmas of breast cancer treatment and increased fracture risk' by Malik. Ann. Oncol. 25 (2014), 1664–1665.
[35] Schimdt, N., Jacob, L., Coleman, R., et al. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res. Treat. 155 (2016), 151–157.
[36] Villa, P., Lassandro, A.P., Amar, I.D., et al. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer. Menopause 23 (2016), 33–39.
[37] Chang, C.H., Chen, S.J., Liu, C.Y., Fracture risk and adjuvant therapies in young breast cancer patients: a population-based study. PLoS One, 10, 2015, e0130725.
[38] Brufsky, A.M., Bosserman, L.D., Caradonna, R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin. Breast Cancer 9 (2009), 77–85.
[39] Goss, P.E., Ingle, J.N., Pritchard, K.I., et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N. Engl. J. Med 375 (2016), 209–219.
[40] V.C. VHI Tjan-Heijnen, P.G. Peer, A.C. Swinkels, C.H. Smorenburg, M. Van der Sangen, J.R. Kroep, H. De Graaf, A.H. Honkoop, F. Erdkamp, F.W. Van den Berkmortel, J.J. Kitzen, M. De Boer, W.K. De Roos, S.C. Linn, A.L. Imholz, C. Seynaeve, First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer. In Presented as an oral presentation at the SABCS on Wednesday, December 7th 2016 (S1-03), 2016.
[41] EJvdVC Blok, E.M. Meershoek-Klein Kranenbarg, H. Putter, J. van den Bosch, E. Maartense, A.E. van Leeuwen-Stok, G.-.J. Liefers, J.W.R. Nortier, E.J.T. Rutgers, J.R. Kroep, Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III. IDEAL trial (BOOG 2006-05). In Presented as an oral presentation at the SABCS on Wednesday, December 7th, 2016 (S1-04), 2016.
[42] EPBH Mamounas, B.C. Lembersky, C.E. Geyer, L. Fehrenbacher, M.L. Graham, S.L. Chia, A.M. Brufsky, B.T. Hennessy, G.S. Soori, S.R. Dakil, T.E. Seay, J.L. Wade, E.C. McCarron, S. Paik, S.M. Swain, D.L. Wickerham, N. Wolmark, A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42. In Presented as an oral presentation at the SABCS on Wednesday, December 7th, 2016 (S1-05), 2016.
[43] Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Am. J. Med., vol. 94, 1993, pp. 646–650.
[44] Kanis, J.A., Melton, L.J. 3rd, Christiansen, C., et al. The diagnosis of osteoporosis. J. Bone Min. Res. 9 (1994), 1137–1141.
[45] Marshall, D., Johnell, O., Wedel, H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996), 1254–1259.
[46] Aapro, M., Abrahamsson, P.A., Body, J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 19 (2008), 420–432.
[47] Body, J.J., Bergmann, P., Boonen, S., et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian bone Club. Osteoporos. Int. 18 (2007), 1439–1450.
[48] Hillner, B.E., Ingle, J.N., Chlebowski, R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21 (2003), 4042–4057.
[49] Reid, D.M., Doughty, J., Eastell, R., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat. Rev., 34(Suppl 1), 2008 (S3-18).
[50] Rochlitz, C., Senn, H.J., Betticher, D., et al. Recommendations of a swiss expert group on the use of bisphosphonates in patients with solid tumors. Swiss Med. Forum, 10, 2010 (In press).
[51] Body, J.J., Terpos, E., Tombal, B., et al. Bone health in the elderly cancer patient: a SIOG position paper. Cancer Treat. Rev. 51 (2016), 46–53.
[52] Rizzoli, R., Body, J.J., DeCensi, A., et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos. Int. 23 (2012), 2567–2576.
[53] Van Poznak, C.H., Temin, S., Yee, G.C., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 29 (2011), 1221–1227.
[54] Leslie, W.D., Rubin, M.R., Schwartz, A.V., Kanis, J.A., Type 2 diabetes and bone. J. Bone Min. Res. 27 (2012), 2231–2237.
[55] Hadji, P., Ziller, M., Albert, U.S., Kalder, M., Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. Br. J. Cancer 102 (2010), 645–650.
[56] Neuner, J.M., Yen, T.W., Sparapani, R.A., et al. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos. Int. 22 (2011), 2847–2855.
[57] Chlebowski, R.T., Chen, Z., Cauley, J.A., et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J. Clin. Oncol., 2010.
[58] Newcomb, P.A., Trentham-Dietz, A., Hampton, J.M., Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br. J. Cancer 102 (2010), 799–802.
[59] Rennert, G., Pinchev, M., Rennert, H.S., Use of bisphosphonates and risk of postmenopausal breast cancer. J. Clin. Oncol., 2010.
[60] Aft, R., Naughton, M., Trinkaus, K., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 11 (2010), 421–428.
[61] Greenberg, S., Park, J.W., Melisko, M.E., et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early stage breast cancer (ESBC): updated results. J. Clin. Oncol., 28(suppl), 2010 (abstr 1002).
[62] Rack, B., Schindlbeck, C., Strobl, B., et al. [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study]. Dtsch. Med. Wochenschr. 133 (2008), 285–289.
[63] Solomayer, E.F., Gebauer, G., Hirnle, P., et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res. 69 (2009), 170s–171s (Abstract 2048).
[64] Coleman, R.E., Winter, M.C., Cameron, D., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer 102 (2010), 1099–1105.
[65] Diel, I.J., Jaschke, A., Solomayer, E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long-term follow-up. Ann. Oncol. 19 (2008), 2007–2011.
[66] Ha, T.C., Li, H., Meta-analysis of clodronate and breast cancer survival. Br. J. Cancer 96 (2007), 1796–1801.
[67] Powles, T., Paterson, A., McCloskey, E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res., 8, 2006, R13.
[68] Saarto, T., Vehmanen, L., Virkkunen, P., Blomqvist, C., Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 43 (2004), 650–656.
[69] Eidtmann, H., de Boer, R., Bundred, N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann. Oncol., 2010.
[70] Gnant, M., Mlineritsch, B., Schippinger, W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360 (2009), 679–691.
[71] Early Breast Cancer Trialists' Collaborative, G., Coleman, R., Powles, T., et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386 (2015), 1353–1361.
[72] Hadji, P., Coleman, R.E., Wilson, C., et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann. Oncol. 27 (2016), 379–390.
[73] De Laet, C., Kanis, J.A., Oden, A., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos. Int. 16 (2005), 1330–1338.
[74] Kanis, J.A., Johnell, O., De Laet, C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 35 (2004), 375–382.
[75] Kanis, J.A., Johansson, H., Oden, A., et al. A family history of fracture and fracture risk: a meta-analysis. Bone 35 (2004), 1029–1037.
[76] Kanis, J.A., Johnell, O., Oden, A., et al. Smoking and fracture risk: a meta-analysis. Osteoporos. Int. 16 (2005), 155–162.
[77] van Staa, T.P., Leufkens, H.G., Abenhaim, L., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 39 (2000), 1383–1389.
[78] Kanis, J.A., Johansson, H., Oden, A., et al. A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Min. Res. 19 (2004), 893–899.
[79] Kanis, J.A., Johansson, H., Johnell, O., et al. Alcohol intake as a risk factor for fracture. Osteoporos. Int. 16 (2005), 737–742.
[80] Waning, D.L., Guise, T.A., Cancer-associated muscle weakness: what's bone got to do with it?. Bone. Rep., 4, 2015, 691.
[81] A. Brufsky, W.G. Harker, J.T. Beck, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in premenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up [poster]. Presented at in: Proceedings of the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 9–13 December 2009 (Abstr 4083). Available at: 〈 http://www.posters2view.com/sabcs09/viewp.php?Nu=4083〉. (Accessed 4 February 2010), 2009.
[82] Hines, S.L., Mincey, B., Dentchev, T., et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res. Treat. 117 (2009), 603–609.
[83] A. Llombart, A. Frassoldati, O. Paija, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at: American Society of Clinical Oncology 2009 Breast Cancer Symposium; October 8-10; San Francisco, CA. Abstract 213, 2009.
[84] Ellis, G.K., Bone, H.G., Chlebowski, R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26 (2008), 4875–4882.
[85] Van Poznak, C., Hannon, R.A., Mackey, J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J. Clin. Oncol. 28 (2010), 967–975.
[86] Greenspan, S.L., Brufsky, A., Lembersky, B.C., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J. Clin. Oncol. 26 (2008), 2644–2652.
[87] Saarto, T., Vehmanen, L., Elomaa, I., et al. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br. J. Cancer 84 (2001), 1047–1051.
[88] Singh, S., Cuzick, J., Edwards, R., et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International breast cancer intervention Study (IBIS-II). Breast Cancer Res. Treat., 106(suppl 1), 2007, S9 (Abstract 28).
[89] Lester, J.E., Dodwell, D., Purohit, O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 14 (2008), 6336–6342.
[90] Confavreux, C.B., Fontana, A., Guastalla, J.P., et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41 (2007), 346–352.
[91] Miller, P.D., Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr. Osteoporos. Rep. 3 (2005), 103–110.
[92] Han, M., Liang, L., Liu, L.R., et al. Liver X receptor gene polymorphisms in tuberculosis: effect on susceptibility. PLoS One, 9, 2014, e95954.
[93] Gnant, M., Pfeiler, G., Dubsky, P.C., et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386 (2015), 433–443.
[94] K. Fizazi, M.A. Carducci, M.R. Smith, et al. A randomized phase lll trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer, in: Proceedings of the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. Abstract LBA4507, June 4–8 2010.
[95] D. Henry, R. von Moos, S. Vadhan-Raj, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, in: Proceedings of the Joint ECCO 15–34th ESMO Multidisciplinary Congress, Berlin, Germany. Abstract 20LBA, 20–24 September 2009.
[96] A. Stopeck, J.J. Body, Y. Fujiwara, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study, in: Proceedings of the Joint ECCO 15–34th ESMO Multidisciplinary Congress, Berlin, Germany. Abstract 2LBA, 20–24 September 2009.
[97] Bone, H.G., Bolognese, M.A., Yuen, C.K., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96 (2011), 972–980.
[98] Miller, P.D., Wagman, R.B., Peacock, M., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J. Clin. Endocrinol. Metab. 96 (2011), 394–402.
[99] Popp, A.W., Zysset, P.K., Lippuner, K., Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos. Int. 27 (2016), 1917–1921.
[101] R. Coleman, N. Bundred, R. de Boer, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST, in: Proceedings of the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX [abstract 4082], December 9–13 2009.
[102] Coleman, R., de Boer, R., Eidtmann, H., et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann. Oncol. 24 (2013), 398–405.
[104] Rennert, G., Pinchev, M., Gronich, N., et al. Oral bisphosphonates and improved survival of breast cancer. Clin. Cancer Res., 2016.
[103] Wagner-Johnston, N.D., Sloan, J.A., Liu, H., et al. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121 (2015), 2537–2543.
[105] Inoue, H., Hirano, A., Ogura, K., et al. The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer. Springerplus, 4, 2015, 303.
[106] Sestak, I., Singh, S., Cuzick, J., et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 15 (2014), 1460–1468.
[107] Greenspan, S.L., Vujevich, K.T., Brufsky, A., et al. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos. Int. 26 (2015), 1857–1864.
[108] Lester, J.E., Dodwell, D., Brown, J.E., et al. Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial. J. Bone Oncol. 1 (2012), 57–62.
[109] Rhee, Y., Song, K., Park, S., et al. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil(R)) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocr. J. 60 (2013), 167–172.
[110] Lomax, A.J., Yee Yap, S., White, K., et al. Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN Trial. J. Bone Oncol. 2 (2013), 145–153.
[111] Rodriguez-Sanz, M., Prieto-Alhambra, D., Servitja, S., et al. AI-related BMD variation in actual practice conditions: a prospective cohort study. Endocr. Relat. Cancer 23 (2016), 303–312.
[112] Hadji, P., Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit. Rev. Oncol. Hematol. 73 (2010), 156–166.
[113] Ziller, V., Kalder, M., Albert, U.S., et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann. Oncol. 20 (2009), 431–436.
[114] Carbonell-Abella, C., Pages-Castella, A., Javaid, M.K., et al. Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: a Population-Based Cohort Study. Calcif. Tissue Int. 97 (2015), 535–541.
[115] Bartl, R., Gotte, S., Hadji, P., Hammerschmidt, T., [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Dtsch. Med. Wochenschr. 131 (2006), 1257–1262.
[116] Hadji, P., Claus, V., Kostev, K., et al. GRAND—The German retrospective cohort analysis on non-adherence in osteoporosis: analysis of persistence with intravenous bisphosphonates in women. Osteoporos. Int. 21 (2010), S168–S169 (Abstr P422).
[117] Hoer, A., Seidlitz, C., Gothe, H., et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3 (2009), 25–30.
[118] Bock, O., Felsenberg, D., Bisphosphonates in the management of postmenopausal osteoporosis—optimizing efficacy in clinical practice. Clin. Inter. Aging 3 (2008), 279–297.
[119] Reginster, J.Y., Adherence and persistence: impact on outcomes and health care resources. Bone 38:Suppl. 2 (2006), S18–S21.
[120] Silverman, S.L., Gold, D.T., Compliance and persistence with osteoporosis therapies. Curr. Rheumatol. Rep. 10 (2008), 118–122.
[121] Howe, T.E., Shea, B., Dawson, L.J., et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst. Rev., 2011, CD000333.
[122] Kemmler, W., Haberle, L., von Stengel, S., Effects of exercise on fracture reduction in older adults: a systematic review and meta-analysis. Osteoporos. Int. 24 (2013), 1937–1950.
[123] Knobf, M.T., Jeon, S., Smith, B., et al. Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy. Breast Cancer Res. Treat. 155 (2016), 491–500.
[124] Servitja, S., Martos, T., Rodriguez Sanz, M., et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. Ther. Adv. Med. Oncol. 7 (2015), 291–296.
[125] Datta, M., Schwartz, G.G., Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy. Crit. Rev. Oncol. Hematol. 88 (2013), 613–624.
[126] Diez-Perez, A., Naylor, K.E., Abrahamsen, B., et al. International osteoporosis foundation and european calcified tissue society working group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos. Int. 28 (2017), 767–774.
[127] Christensen, L., Iqbal, S., Macarios, D., et al. Cost of fractures commonly associated with osteoporosis in a managed-care population. J. Med. Econ. 13 (2010), 302–313.
[128] Becker, D.J., Yun, H., Kilgore, M.L., et al. Health services utilization after fractures: evidence from medicare. J. Gerontol. A Biol. Sci. Med. Sci., 2010.
[129] Shi, N., Foley, K., Lenhart, G., Badamgarav, E., Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 45 (2009), 1084–1090.
[130] Hernlund, E., Svedbom, A., Ivergard, M., et al. osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International osteoporosis foundation (IOF) and the European Federation of pharmaceutical industry Associations (EFPIA). Arch. Osteoporos., 8, 2013, 136.
